 Westport, CT, July 12, 2021 GLOBE NEWSWIRE -- BioSig Technologies, Inc. Nasdaq: BSGM BioSig or the Company, a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EPtm 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. Davids Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA. 